The prevalence of severe refractory asthma.
Hekking PW, Wener RR, Amelink M, Zwinderman AH, Bouvy ML, Bel EH.
J Allergy Clin Immunol. 2015 Apr;135(4):896-902. doi: 10.1016/j.jaci.2014.08.042. Epub 2014 Oct 16.
Feline Asthma: Diagnostic and Treatment Update.
Trzil JE.
Vet Clin North Am Small Anim Pract. 2020 Mar;50(2):375-391. doi: 10.1016/j.cvsm.2019.10.002. Epub 2019 Dec 4.
Refractory neutrophilic asthma and ciliary genes.
Guntur VP, Manka LA, Moore CM, Wynn E, Vladar EK, Alam R, Pham TH, Fingerlin TE, Martin RJ.
J Allergy Clin Immunol. 2022 Jun;149(6):1970-1980. doi: 10.1016/j.jaci.2021.12.761. Epub 2022 Jan 13.
Refractory asthma.
McGeehan M, Busse WW.
Med Clin North Am. 2002 Sep;86(5):1073-90. doi: 10.1016/s0025-7125(02)00034-2.
Refractory asthma: mechanisms, targets, and therapy.
Trevor JL, Deshane JS.
Allergy. 2014 Jul;69(7):817-27. doi: 10.1111/all.12412. Epub 2014 Apr 29.
Nationwide survey of refractory asthma with bronchiectasis by inflammatory subtypes.
Nomura N, Matsumoto H, Yokoyama A, Nishimura Y, Asano K, Niimi A, Tohda Y, Harada N, Nagase H, Nagata M, Inoue H, Kondo M, Horiguchi T, Miyahara N, Hizawa N, Hojo M, Hattori N, Hashimoto N, Yamasaki A, Kadowaki T, Kimura T, Miki M, Taniguchi H, Toyoshima M, Kawamura T, Matsuno O, Sato Y, Sunadome H, Nagasaki T, Oguma T, Hirai T; BEXAS study.
Respir Res. 2022 Dec 20;23(1):365. doi: 10.1186/s12931-022-02289-y.
Tezepelumab for refractory eosinophilic granulomatosis with polyangiitis-related asthma.
Vincent-Galtié N, Marquant Q, Catherinot E, Ackermann F, Magnan A, Tcherakian C, Groh M.
Respir Res. 2024 Jul 11;25(1):272. doi: 10.1186/s12931-024-02888-x.
Molecular Targets for Biological Therapies of Severe Asthma.
Pelaia C, Crimi C, Vatrella A, Tinello C, Terracciano R, Pelaia G.
Front Immunol. 2020 Nov 30;11:603312. doi: 10.3389/fimmu.2020.603312. eCollection 2020.
Severe refractory asthma: an update.
Wener RR, Bel EH.
Eur Respir Rev. 2013 Sep 1;22(129):227-35. doi: 10.1183/09059180.00001913.
The inflammatory profile of exacerbations in patients with severe refractory eosinophilic asthma receiving mepolizumab (the MEX study): a prospective observational study.
McDowell PJ, Diver S, Yang F, Borg C, Busby J, Brown V, Shrimanker R, Cox C, Brightling CE, Chaudhuri R, Pavord ID, Heaney LG; Medical Research Council: Refractory Asthma Stratification Programme (RASP-UK Consortium).
Lancet Respir Med. 2021 Oct;9(10):1174-1184. doi: 10.1016/S2213-2600(21)00004-7. Epub 2021 May 7.
